Elanco Animal Health Hits New 52-Week High at $22.95

Elanco Animal Health, Inc. has reached a significant milestone by hitting a new 52-week high of USD 22.95 on November 3, 2025. This achievement underscores the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 9,464 million.
Over the past year, Elanco has demonstrated a robust performance, with a 25.27% increase, outperforming the S&P 500, which recorded a 19.89% gain during the same period. The company's price-to-earnings (P/E) ratio stands at 14.00, indicating a favorable valuation relative to its earnings. Additionally, Elanco maintains a debt-to-equity ratio of 0.54, reflecting a manageable level of debt.

Despite a dividend yield of 0.00%, the company has achieved a return on equity of 7.26%, showcasing its ability to generate profit from shareholders' equity. The stock's previous 52-week low was recorded at USD 8.02, highlighting the significant upward movement in its price. This milestone reflects Elanco's ongoing efforts and position within the competitive landscape of the pharmaceuticals and biotechnology industry.